ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progessive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs

Trial Profile

ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progessive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs

Completed
Phase of Trial: Phase II

Latest Information Update: 18 May 2012

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; CNS cancer; Glioblastoma; Glioma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 May 2012 Additional lead trial centre and actual patient number (105) added as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Actual end date (June 2009) added as reported by ClinicalTrials.gov.
    • 07 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top